Interaction of vasculotropin/vascular endothelial cell growth factor with human umbilical vein endothelial cells: binding, internalization, degradation, and biological effects

Détails

ID Serval
serval:BIB_A97FF60A99DB
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Interaction of vasculotropin/vascular endothelial cell growth factor with human umbilical vein endothelial cells: binding, internalization, degradation, and biological effects
Périodique
Journal of Cellular Physiology
Auteur⸱e⸱s
Bikfalvi  A., Sauzeau  C., Moukadiri  H., Maclouf  J., Busso  N., Bryckaert  M., Plouet  J., Tobelem  G.
ISSN
0021-9541 (Print)
Statut éditorial
Publié
Date de publication
10/1991
Volume
149
Numéro
1
Pages
50-9
Notes
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Oct
Résumé
Vasculotropin/vascular endothelial cell growth factor (VAS/VEGF) is a newly purified growth factor with a unique specificity for vascular endothelial cells. We have investigated the interactions of VAS/VEGF with human umbilical vein endothelial cells (HUVE cells). 125I-VAS/VEGF was found to HUVE cells in a saturable manner with a half-maximum binding at 2.8 ng/ml. Scatchard analysis did show two classes of high-affinity binding sites. The first class displayed a dissociation constant of 9 pM with 500 sites/cell. The dissociation constant and the number of binding sites of the second binding class were variable for different HUVE cell cultures (KD = 179 +/- 101 pM, 5,850 +/- 2,950 sites/cell). Half-maximal inhibition of 125I-VAS/VEGF occurred with a threefold excess of unlabeled ligand. Basic fibroblast growth factor (bFGF) and heparin did not compete with 125I-VAS/VEGF binding. In contrast, suramin and protamin sulfate completely displaced 125I-VAS/VEGF binding from HUVE cells. VAS/VEGF was shown to be internalized in HUVE cells. Maximum internalization (55% of total cell-associated radioactivity) was observed after 30 min. 125I-VAS/VEGF was completely degraded 2-3 hr after binding. At 3 hr, the trichloroacetic acid (TCA)-soluble radioactivity accumulated in the medium was 60% of the total radioactivity released by HUVE cells. No degradation fragment of 125I-VAS/VEGF was observed. Chloroquine completely inhibited degradation. VAS/VEGF was able to induce angiogenesis in vitro in HUVE cells. However, it did not significantly modulate urokinase-type plasminogen activator (u-PA), tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor (PAI-1), and tissue factor (TF). Prostacyclin production was only stimulated at very high VAS/VEGF concentrations. Taken together, these results indicate that VAS/VEGF might be a potent inducer of neovascularization resulting from a direct interaction with endothelial cells. The angiogenic activity seems to be independent of the plasminogen activator or inhibitor system.
Mots-clé
Cells, Cultured Endothelial Growth Factors/*metabolism/pharmacology Endothelium, Vascular/cytology/drug effects/*metabolism Epoprostenol/metabolism Growth Substances/*metabolism/pharmacology Humans Kinetics Lymphokines/*metabolism/pharmacology Neovascularization, Pathologic Plasminogen Inactivators/metabolism Thromboplastin/metabolism Tissue Plasminogen Activator/metabolism Umbilical Veins Urinary Plasminogen Activator/metabolism Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factors
Pubmed
Web of science
Création de la notice
25/01/2008 9:29
Dernière modification de la notice
20/08/2019 16:13
Données d'usage